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Yes. Patients with type 2 diabetes benefi t 
from case management, as evidenced by 
decreased glycated hemoglobin (HbA1c). 
The improvement in HbA1c appeared 
larger when case managers could make 
changes in medications independently and 
multidisciplinary teams were used (strength 
of recommendation [SOR]: C, 2 meta-
analyses of randomized controlled trials 
[RCTs] with consistent disease-oriented 
fi ndings). Patients with type 1 diabetes 
who have case management and “intense 
control” experience fewer cardiovascular 
events and decreased retinopathy and 
clinical neuropathy (SOR: B, 1 large, good-
quality RCT).
Evidence-based answer
Does case management 
improve diabetes outcomes?
❚ Evidence summary
The many defi nitions used to describe 
case management present a challenge in 
summarizing its effect.1,2 A Cochrane re-
view of case management by a “diabetes 
specialist nurse/nurse case manager” in-
cluded 6 trials and 1382 patients with ei-
ther type 1 or type 2 diabetes. It revealed 
a short-term benefi t (lower HbA1c) in 
only 1 trial at 6 months and no difference 
in HbA1c or improvement in quality of 
life in any trial at 12 months.3
However, a review of 66 RCTs of 
case management for type 2 diabetes 
found a mean reduction in HbA1c of 
0.52% (95% confi dence interval [CI], 
0.31-0.73) after adjusting for study size 
(smaller studies tended to report larger 
changes) and whether or not patients 
were “poorly controlled” at baseline 
(studies with higher HbA1c levels at 
baseline also reported larger effects).1 
The most striking HbA1c reduction oc-
curred when case managers could make 
medication adjustments without physi-
cian approval (change in HbA1c=0.80%; 
95% CI, 0.51-1.10). Moreover, using a 
multidisciplinary team reduced HbA1c 
by 0.37% more than interventions with-
out such a team (95% CI, 0.16-0.58).
The authors of an earlier review of 15 
case management studies for type 2 diabe-
tes concluded that case management alone 
was benefi cial, resulting in an HbA1c 
improvement of 0.40% (interquartile 
range=0.46-0.65).4 However, they further 
noted that studies that showed case man-
agement to be effective also involved dis-
ease management or included additional 
interventions such as education, remind-
ers, or other supports.
But studies don’t always show 
robust outcomes
Outcomes in other studies often aren’t 
as robust. In the year-long Informatics 
for Diabetes Education and Telemedi-
cine (IDEATel) project,5 for example, 
nurse case managers supervised by dia-
betologists and working with primary 
care physicians were able to direct care 
based on pre-established algorithms. 
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Those in the intervention group with a 
baseline HbA1c >7 had an HbA1c reduc-
tion of 0.32% and small but statistically 
signifi cant reductions in blood pressure 
(3.4 mm Hg systolic and 1.9 mm Hg 
diastolic) and low-density lipoprotein 
(9.5 mg/dL).
Intensive control produces 
positive results, a few harms
The Diabetes Control and Complica-
tions Trial (DCCT)6 showed that, in pa-
tients with type 1 diabetes, “intensive” 
diabetic control managed by a large 
team of health care providers for an av-
erage of 6.5 years reduced the develop-
ment of retinopathy (number needed to 
treat [NNT]=6; 95% CI, 5-7), progres-
sion of retinopathy (NNT=5; 95% CI, 
4-7), and development or progression of 
clinical neuropathy (NNT=13; 95% CI, 
11-18).7 Intensive therapy also caused 
harms, including episodes of hypoglyce-
mia (number needed to harm [NNH]=3), 
and “hypoglycemia requiring assistance” 
(NNH=36).
In the follow-up to DCCT—the 
Epidemiology of Diabetes Interventions 
and Complications study (EDIC)—
93% of the patients in the original co-
hort were followed for an average of 
17 years.8 The risk of developing any 
predetermined cardiovascular event 
was 42% less in the intervention group 
(NNT=14; 95% CI, 9-65), and the com-
bined risk of death, nonfatal myocardi-
al infarction, or stroke was 57% lower 
(NNT=10; 95% CI, 7-49). Harms, such 
as hypoglycemia, were not reported.
Recommendations
According to the American Diabetes As-
sociation, patients with diabetes should 
receive medical care from a physician-
coordinated team, which may include 
nurse practitioners, physician’s assistants, 
nurses, dieticians, pharmacists, and men-
tal health professionals.9
The Centers for Disease Control and 
Prevention strongly recommends that 
patients with diabetes be assigned “a 
case manager to plan, coordinate, and in-
tegrate care,” because case management 
improves glycemic control and physician 
monitoring.10
The American Association of Clinical 
Endocrinologists states: “Managing dia-
betes mellitus requires a team approach to 
patient care. However, because diabetes is 
primarily a self-managed disease, educa-
tion in self-management skills is essential 
in implementing interventions.”11 ■
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